Search

Your search keyword '"Blank, Norbert"' showing total 405 results
Start Over Author "Blank, Norbert"
405 results on '"Blank, Norbert"'

4. Treat-to-target strategies for the management of familial Mediterranean Fever in children

Author

Ehlers, Lisa, Rolfes, Elisabeth, Lieber, Mareike, Müller, Dominik, Lainka, Elke, Gohar, Faekah, Klaus, Günter, Girschick, Hermann, Hörstermann, Jana, Kümmerle-Deschner, Jasmin, Brunner, Jürgen, Palm-Beden, Katharina, Tenbrock, Klaus, von Wrangel, Lusine, Faßhauer, Maria, Blank, Norbert, Trauzeddel, Ralf, von Stuckrad, Anne Sae Lim, Higgins, Sonja, Welzel, Tatjana, Lutz, Thomas, Hentgen, Véronique, Foell, Dirk, Wittkowski, Helmut, and Kallinich, Tilmann

Published
2023
Full Text
View/download PDF

11. Autologous hematopoietic stem cell transplantation improves long-term survival—data from a national registry

Author

Blank, Norbert, Schmalzing, Marc, Moinzadeh, Pia, Oberste, Max, Siegert, Elise, Müller-Ladner, Ulf, Riemekasten, Gabriela, Günther, Claudia, Kötter, Ina, Zeidler, Gabriele, Pfeiffer, Christiane, Juche, Aaron, Jandova, Ilona, Ehrchen, Jan, Susok, Laura, Schmeiser, Tim, Sunderkötter, Cord, Distler, Jörg H. W., Worm, Margitta, Kreuter, Alexander, Keyßer, Gernot, Lorenz, Hanns-Martin, Krieg, Thomas, Hunzelmann, Nicolas, and Henes, Jörg

Published
2022
Full Text
View/download PDF

13. Fibroblast activation protein inhibitor-positron emission tomography in aortitis: fibroblast pathology in active inflammation and remission.

Author

Röhrich, Manuel, Rosales, Juan J, Hoppner, Jorge, Kvacskay, Peter, Blank, Norbert, Loi, Lisa, Paech, Daniel, Schreckenberger, Mathias, Giesel, Frederik, Kauczor, Hans Ulrich, Lorenz, Hanns Martin, Haberkorn, Uwe, and Merkt, Wolfgang

Subjects
VASCULITIS, PEARSON correlation (Statistics), RESEARCH funding, PILOT projects, FISHER exact test, POSITRON emission tomography, DISEASE remission, RETROSPECTIVE studies, MAGNETIC resonance imaging, DESCRIPTIVE statistics, FIBROBLASTS, RESEARCH, TAKAYASU arteritis, INFLAMMATION, DIGITAL image processing, DATA analysis software, TIME
Abstract

Objectives Epigenetically modified fibroblasts contribute to chronicity in inflammatory diseases. Reasons for the relapsing character of large vessel vasculitis (LVV) remain obscure, including the role of fibroblasts, in part due to limited access to biopsies of involved tissue.68Ga FAPI-46 (FAPI)-PET/CT detects activated fibroblasts in vivo. In this exploratory pilot study, we tested the detection of fibroblast activation in vessel walls using FAPI-PET/CT in LVV with aortitis. Methods Eight LVV patients with aortitis and eight age- and gender-matched controls were included. The distribution of FAPI uptake was evaluated in the aorta and large vessels. FAPI-uptake was compared with MRI inflammatory activity scores. Imaging results were compared with clinical parameters such as serum inflammatory markers, time of remission and medication. Results Three aortitis patients were clinically active and five in remission. Irrespective of activity, FAPI uptake was significantly enhanced in aortitis compared with controls. Patients in remission had a mean duration of remission of 2.8 years (range 1–4 years), yet significant FAPI uptake in the vessel wall was found. In remitted aortitis, MRI inflammatory scores were close to be negative, while in 4/5 patients visually identifiable FAPI uptake was observed. Conclusions This pilot feasibility study shows significant tracer uptake in the aortic walls in LVV. FAPI positivity indicates ongoing fibroblast pathology in clinically remitted LVV. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Biomarker-based renal response and progression criteria in AA amyloidosis: results from the testing cohort of the Pavia-Heidelberg study

Author

Basset, Marco, primary, Hegenbart, Ute, primary, Obici, Laura, primary, Riva, Eloisa, primary, Milani, Paolo, primary, Pasquinucci, Ettore, primary, Foli, Andrea, primary, Nanci, Martina, primary, Ciardo, Martina, primary, Corpina, Chiara, primary, Bellofiore, Claudia, primary, Benigna, Francesca, primary, Benvenuti, Pietro, primary, Damiano, Giuseppe, primary, Mussinelli, Roberta, primary, Nuvolone, Mario, primary, Albertini, Riccardo, primary, Merlini, Giampaolo, primary, Schönland, Stefan, primary, Blank, Norbert, primary, and Palladini, Giovanni, primary

Published
2024
Full Text
View/download PDF

18. Long-term safety and effectiveness of canakinumab in patients with monogenic autoinflammatory diseases: results from the interim analysis of the RELIANCE registry

Author

Kuemmerle-Deschner, Jasmin B, primary, Kallinich, Tilmann, additional, Henes, Joerg, additional, Kortus-Götze, Birgit, additional, Oommen, Prasad T, additional, Rech, Juergen, additional, Krickau, Tobias, additional, Weller-Heinemann, Frank, additional, Horneff, Gerd, additional, Janda, Aleš, additional, Foeldvari, Ivan, additional, Schuetz, Catharina, additional, Dressler, Frank, additional, Borte, Michael, additional, Hufnagel, Markus, additional, Meier, Florian, additional, Fiene, Michael, additional, Andreica, Ioana, additional, Weber-Arden, Julia, additional, and Blank, Norbert, additional

Published
2024
Full Text
View/download PDF

19. Third-generation CD19.CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis

Author

Merkt, Wolfgang, primary, Freitag, Merle, additional, Claus, Maren, additional, Kolb, Philipp, additional, Falcone, Valeria, additional, Röhrich, Manuel, additional, Rodon, Lea, additional, Deicher, Franca, additional, Andreeva, Ivana, additional, Tretter, Theresa, additional, Tykocinski, Lars-Oliver, additional, Blank, Norbert, additional, Watzl, Carsten, additional, Schmitt, Anita, additional, Sauer, Tim, additional, Müller-Tidow, Carsten, additional, Polke, Markus, additional, Heußel, Claus Peter, additional, Dreger, Peter, additional, Lorenz, Hanns-Martin, additional, and Schmitt, Michael, additional

Published
2023
Full Text
View/download PDF

20. Development and Validation of Staging Systems for AA Amyloidosis

Author

Basset, Marco, Schönland, Stefan O., Obici, Laura, Günther, Janine, Riva, Eloisa, Dittrich, Tobias, Milani, Paolo, Ferretti, Virginia Valeria, Pasquinucci, Ettore, Foli, Andrea, Kimmich, Christoph, Nanci, Martina, Bellofiore, Claudia, Benigna, Francesca, Beimler, Jörg, Benvenuti, Pietro, Fabris, Francesca, Mussinelli, Roberta, Nuvolone, Mario, Klersy, Catherine, Albertini, Riccardo, Merlini, Giampaolo, Hegenbart, Ute, Palladini, Giovanni, and Blank, Norbert

Published
2024
Full Text
View/download PDF

22. Clinical presentation and genetic variants in patients with autoinflammatory diseases: results from the German GARROD registry

Author

Blank, Norbert, primary, Kötter, Ina, additional, Schmalzing, Marc, additional, Rech, Jürgen, additional, Krause, Karoline, additional, Köhler, Birgit, additional, Kaudewitz, Dorothee, additional, Nitschke, Martin, additional, Haas, Christian S., additional, Lorenz, Hanns-Martin, additional, and Krusche, Martin, additional

Published
2023
Full Text
View/download PDF

25. Characteristics and outcomes of SARS-CoV-2 breakthrough infections among double-vaccinated and triple-vaccinated patients with inflammatory rheumatic diseases

Author

Hasseli, Rebecca, primary, Richter, Jutta G., additional, Hoyer, Bimba Franziska, additional, Lorenz, Hanns-Martin, additional, Pfeil, Alexander, additional, Regierer, Anne Constanze, additional, Schmeiser, Tim, additional, Strangfeld, Anja, additional, Voll, Reinhard E, additional, Krause, Andreas, additional, Reckert, Sabine, additional, Gräßler, Anett, additional, Saar, Petra, additional, Kapelle, Andreas, additional, Backhaus, Marina, additional, Blank, Norbert, additional, Henes, Joerg, additional, Osiek, Silke, additional, Knothe, Anna, additional, Hoese, Guido, additional, Brandt-Jürgens, Jan, additional, Maltzahn, Anja, additional, Specker, Christof, additional, Müller-Ladner, Ulf, additional, and Schulze-Koops, Hendrik, additional

Published
2023
Full Text
View/download PDF

26. Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study)

Author

Pan, Zixuan, Marra, Alberto M., Benjamin, Nicola, Eichstaedt, Christina A., Blank, Norbert, Bossone, Eduardo, Cittadini, Antonio, Coghlan, Gerry, Denton, Christopher P., Distler, Oliver, Egenlauf, Benjamin, Fischer, Christine, Harutyunova, Satenik, Xanthouli, Panagiota, Lorenz, Hanns-Martin, and Grünig, Ekkehard

Published
2019
Full Text
View/download PDF

28. Autologous haematopoietic stem cell transplantation for multiple sclerosis: a position paper and registry outline.

Author

Bayas, Antonios, Berthele, Achim, Blank, Norbert, Dreger, Peter, Faissner, Simon, Friese, Manuel A., Gerdes, Lisa-Ann, Grauer, Oliver Martin, Häussler, Vivien, Heesen, Christoph, Janson, Dietlinde, Korporal-Kuhnke, Mirjam, Kowarik, Markus, Kröger, Nikolaus, Lünemann, Jan D., Martin, Roland, Meier, Uwe, Meuth, Sven, Muraro, Paolo, and Platten, Michael

Subjects
STEM cells, MULTIPLE sclerosis, DISEASE progression, MAGNETIC resonance imaging
Abstract

Background: While substantial progress has been made in the development of disease-modifying medications for multiple sclerosis (MS), a high percentage of treated patients still show progression and persistent inflammatory activity. Autologous haematopoietic stem cell transplantation (AHSCT) aims at eliminating a pathogenic immune repertoire through intense short-term immunosuppression that enables subsequent regeneration of a new and healthy immune system to re-establish immune tolerance for a long period of time. A number of mostly open-label, uncontrolled studies conducted over the past 20 years collected about 4000 cases. They uniformly reported high efficacy of AHSCT in controlling MS inflammatory disease activity, more markedly beneficial in relapsing-remitting MS. Immunological studies provided evidence for qualitative immune resetting following AHSCT. These data and improved safety profiles of transplantation procedures spurred interest in using AHSCT as a treatment option for MS. Objective: To develop expert consensus recommendations on AHSCT in Germany and outline a registry study project. Methods: An open call among MS neurologists as well as among experts in stem cell transplantation in Germany started in December 2021 to join a series of virtual meetings. Results: We provide a consensus-based opinion paper authored by 25 experts on the up-to-date optimal use of AHSCT in managing MS based on the Swiss criteria. Current data indicate that patients who are most likely to benefit from AHSCT have relapsing-remitting MS and are young, ambulatory and have high disease activity. Treatment data with AHSCT will be collected within the German REgistry Cohort of autologous haematopoietic stem CeLl trAnsplantation In MS (RECLAIM). Conclusion: Further clinical trials, including registry-based analyses, are urgently needed to better define the patient characteristics, efficacy and safety profile of AHSCT compared with other high-efficacy therapies and to optimally position it as a treatment option in different MS disease stages. Plain language summary: Autologous haematopoietic stem cell transplantation for multiple sclerosis Substantial progress has been made in the development of disease-modifying medications for multiple sclerosis (MS) during the last 20 years. However, in a relevant percentage of patients, the disease cannot completely be contained. Autologous haematopoietic stem cell transplantation (AHSCT) enables rebuilding of a new and healthy immune system and to potentially stop the autoimmune disease process for a long time. A number of studies documenting 4000 cases cumulatively over the past 20 years reported high efficacy of AHSCT in controlling MS inflammatory disease activity. These data and improved safety profiles of the treatment procedures spurred interest in using AHSCT as a treatment option for MS. An open call among MS neurologists as well as among experts in stem cell transplantation in Germany started in December 2021 to join a series of video calls to develop recommendations and outline a registry study project. We provide a consensus-based opinion paper authored by 25 experts on the up-to-date optimal use of AHSCT in managing MS. Current data indicate that patients are most likely to benefit from AHSCT if they are young, ambulatory, with high disease activity, that is, relapses or new magnetic resonance imaging (MRI) lesions. Treatment data with AHSCT will be collected within the German REgistry Cohort of autoLogous haematopoietic stem cell transplantation MS (RECLAIM). Further clinical trials including registry-based analyses and systematic follow-up are urgently needed to better define the optimal patient characteristics as well as the efficacy and safety profile of AHSCT compared with other high-efficacy therapies. These will help to position AHSCT as a treatment option in different MS disease stages. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

29. Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis.

Author

Kreuter, Michael, Bonella, Francesco, Blank, Norbert, Riemekasten, Gabriela, Müller-Ladner, Ulf, Henes, Jörg, Siegert, Elise, Günther, Claudia, Kötter, Ina, Pfeiffer, Christiane, Schmalzing, Marc, Zeidler, Gabriele, Korsten, Peter, Susok, Laura, Juche, Aaron, Worm, Margitta, Jandova, Ilona, Ehrchen, Jan, Sunderkötter, Cord, and Keyßer, Gernot

Subjects
EVALUATION of medical care, CARBON monoxide, CONFIDENCE intervals, INTERSTITIAL lung diseases, SYSTEMIC scleroderma, RETROSPECTIVE studies, GASTROESOPHAGEAL reflux, PROTON pump inhibitors, RISK assessment, VITAL capacity (Respiration), PEARSON correlation (Statistics), CHI-squared test, KAPLAN-Meier estimator, DESCRIPTIVE statistics, PROGRESSION-free survival, OVERALL survival, DISEASE risk factors, DISEASE complications
Abstract

Objectives Gastroesophageal reflux disease (GERD) occurs frequently in patients with SSc. We investigated whether the presence of GERD and/or the use of anti-acid therapy, specifically proton-pump inhibitors (PPIs), are associated with long-term outcomes, especially in SSc-associated interstitial lung disease (SSc-ILD). Methods We retrospectively analysed patients with SSc and SSc-ILD from the German Network for Systemic Sclerosis (DNSS) database (2003 onwards). Kaplan–Meier analysis compared overall survival (OS) and progression-free survival (PFS) in patients with GERD vs without GERD (SSc and SSc-ILD), and PPI vs no PPI use (SSc-ILD only). Progression was defined as a decrease in either percentage predicted forced vital capacity of ≥10% or single-breath diffusing capacity for carbon monoxide of ≥15%, or death. Results It was found that 2693/4306 (63%) registered patients with SSc and 1204 / 1931 (62%) with SSc-ILD had GERD. GERD was not associated with decreased OS or decreased PFS in patients in either cohort. In SSc-ILD, PPI use was associated with improved OS vs no PPI use after 1 year [98.4% (95% CI: 97.6, 99.3); n  = 760 vs 90.8% (87.9–93.8); n  = 290] and after 5 years [91.4% (89.2–93.8); n  = 357 vs 70.9% (65.2–77.1); n  = 106; P  < 0.0001]. PPI use was also associated with improved PFS vs no PPI use after 1 year [95.9% (94.6–97.3); n  = 745 vs 86.4% (82.9–90.1); n  = 278] and after 5 years [66.8% (63.0–70.8); n  = 286 vs 45.9% (39.6–53.2); n  = 69; P  < 0.0001]. Conclusion GERD had no effect on survival in SSc or SSc-ILD. PPIs improved survival in patients with SSc-ILD. Controlled, prospective trials are needed to confirm this finding. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

30. Diagnosis and treatment of adult-onset Still’s disease: a concise summary of the German society of rheumatology S2 guideline

Author

Vordenbäumen, Stefan, primary, Feist, Eugen, additional, Rech, Jürgen, additional, Fleck, Martin, additional, Blank, Norbert, additional, Haas, Johannes-Peter, additional, Kötter, Ina, additional, Krusche, Martin, additional, Chehab, Gamal, additional, Hoyer, Bimba, additional, Kiltz, Uta, additional, Fell, Dorothea, additional, Reiners, Julia, additional, Weseloh, Christiane, additional, Schneider, Matthias, additional, and Braun, Jürgen, additional

Published
2022
Full Text
View/download PDF

31. DGRh-S2e-Leitlinie

Author

Vordenbäumen, Stefan, primary, Feist, Eugen, additional, Rech, Jürgen, additional, Fleck, Martin, additional, Blank, Norbert, additional, Haas, Johannes-Peter, additional, Kötter, Ina, additional, Krusche, Martin, additional, Chehab, Gamal, additional, Hoyer, Bimba, additional, Kiltz, Uta, additional, Fell, Dorothea, additional, Reiners, Julia, additional, Weseloh, Christiane, additional, Schneider, Matthias, additional, and Braun, Jürgen, additional

Published
2022
Full Text
View/download PDF

32. Adressen

Author

Breusch, Steffen, primary, Clarius, Michael, additional, Mau, Hans, additional, Sabo, Desiderius, additional, Abel, Rainer, additional, Ackermann, Ole, additional, Akbar, Michael, additional, Bernd, Ludger, additional, Biglari, Bahram, additional, Binder, Johannes, additional, Blank, Norbert, additional, Dormann, Arno J., additional, Ernst, Olaf, additional, Franz, Matthias, additional, Fuchs, Alfons, additional, Kloth, Jost Karsten, additional, Krämer, Philipp, additional, Küpper, Helmut J., additional, Lorenz, Hanns-Martin, additional, Maichl, Franz-Peter, additional, Michel, Johanna, additional, Mohr, Guido, additional, Nowak, Elisabeth, additional, von Reumont, Anne, additional, Scheller, Gerhard, additional, Schiltenwolf, Marcus, additional, Schmidt, Hermann, additional, Schmidt, Michael, additional, Schmitt, Holger, additional, Schneidmüller, Dorien, additional, Steinmetz, Gabriele, additional, Strobl, Walter Michael, additional, Türk, Ansgar, additional, Unglaub, Frank, additional, Weber, Marc-André, additional, Werber, Andreas, additional, Wiedenhöfer, Bernd, additional, Zeifang, Felix, additional, Hundt, Guido, additional, Bouman, Hans-Werner, additional, Ewerbeck, Volker, additional, Göttle, Beate, additional, and Riewe, Hanne Lore, additional

Published
2017
Full Text
View/download PDF

33. Rheumaorthopädie

Author

Blank, Norbert, primary, Lorenz, Hanns-Martin, additional, Mau, Hans, additional, and Breusch, Steffen, additional

Published
2017
Full Text
View/download PDF

36. Langfristige Wirksamkeit und Sicherheit von Canakinumab bei Patienten mit TRAPS (Tumornekrose­faktor-Rezeptor­assoziiertes periodisches Syndrom) – Zwischenanalyse des RELIANCE-Registers

Author

Blank, Norbert, Schütz, Catharina, Henes, Jörg, Kallinich, Tilmann, Oommen, Prasad T., Borte, Michael, Hufnagel, Markus, Janda, Ales, Weber-Arden, Julia, and Kümmerle-Deschner, Jasmin B.

Subjects
Medicine and health
Abstract

Einleitung: TRAPS (Tumornekrosefaktor-Rezeptor-assoziiertes periodisches Syndrom) ist eine seltene hereditäre autoinflammatorische Erkrankung, die durch periodisches Fieber sowie schwere systemische und Organentzündungen gekennzeichnet ist. Eine erfolgreiche Behandlung wurde mit dem Interleukin-1β-Inhibitor [zum vollständigen Text gelangen Sie über die oben angegebene URL]

Published
2022
Full Text
View/download PDF

37. Langzeitwirksamkeit und Sicherheit von Canakinumab bei Patienten mit HIDS (Hyper-IgD-Syndrom) – Interimsanalyse des RELIANCE-Registers

Author

Oommen, Prasad T., Kallinich, Tilmann, Rech, Jürgen, Blank, Norbert, Weber-Arden, Julia, and Kümmerle-Deschner, Jasmin B.

Subjects
Medicine and health
Abstract

Einleitung: Hyper-IgD-Syndrom/Mevalonatkinase-Defizienz (HIDS/MKD) ist eine seltene autoinflammatorische Erkrankung, die durch einen Defekt im Gen für die Mevalonatkinase verursacht wird. Die Behandlung mit dem Interleukin-1β-Inhibitor Canakinumab (CAN), der seit 2017 (Ilaris, INN-canakinumab [zum vollständigen Text gelangen Sie über die oben angegebene URL]

Published
2022
Full Text
View/download PDF

38. Impfsicherheit unter Canakinumab bei Patienten mit autoinflammatorischen periodischen Syndromen – Interimsanalyse des RELIANCE-Registers

Author

Kümmerle-Deschner, Jasmin B., Henes, Jörg, Kortus-Götze, Birgit, Kallinich, Tilmann, Oommen, Prasad T., Rech, Jürgen, Krickau, Tobias, Weller-Heinemann, Frank, Horneff, Gerd, Janda, Ales, Foeldvari, Ivan, Meier, Florian, Schütz, Catharina, Dressler, Frank, Borte, Michael, Hufnagel, Markus, Fiene, Michael, Weber-Arden, Julia, and Blank, Norbert

Subjects
Medicine and health
Abstract

Einleitung: Die Behandlung autoinflammatorischer periodischer Syndrome mit dem Interleukin-1β-Inhibitor Canakinumab (CAN) hat sich in klinischen Studien und in der Praxis als sicher und wirksam erwiesen. Patienten wird unter der Therapie ebenso wie der Allgemeinbevölkerung die Schutzimpfung [zum vollständigen Text gelangen Sie über die oben angegebene URL]

Published
2022
Full Text
View/download PDF

39. Langzeitsicherheit und Wirksamkeit von Canakinumab bei Cryopyrin-assoziierten periodischen Syndromen (CAPS) – 36-Monats-Daten aus dem RELIANCE-Register

Author

Kümmerle-Deschner, Jasmin B., Kortus-Götze, Birgit, Oommen, Prasad T., Janda, Ales, Rech, Jürgen, Schütz, Catharina, Kallinich, Tilmann, Weller-Heinemann, Frank, Horneff, Gerd, Foeldvari, Ivan, Meier, Florian, Borte, Michael, Krickau, Tobias, Weber-Arden, Julia, and Blank, Norbert

Subjects
Medicine and health
Abstract

Einleitung: Cryopyrin-assoziierte periodische Syndrome (CAPS) sind monogene autoinflammatorische Erkrankungen mit schwerer systemischer Entzündung. Der IL-1β-Inhibitor Canakinumab (CAN) führt sowohl in klinischen Studien als auch in der Praxis zu einer schnellen Remission der CAPS-Symptome. [zum vollständigen Text gelangen Sie über die oben angegebene URL]

Published
2022
Full Text
View/download PDF

40. Langzeitwirksamkeit und Sicherheit von Canakinumab bei Patienten mit familiärem Mittelmeerfieber (FMF) – Zwischenanalyse des RELIANCE-Registers

Author

Henes, Jörg, Kümmerle-Deschner, Jasmin B., Krickau, Tobias, Kallinich, Tilmann, Dressler, Frank, Horneff, Gerd, Meier, Florian, Foeldvari, Ivan, Weller-Heinemann, Frank, Kortus-Götze, Birgit, Hufnagel, Markus, Rech, Jürgen, Oommen, Prasad T., Weber-Arden, Julia, and Blank, Norbert

Subjects
Medicine and health
Abstract

Einleitung: Familiäres Mittelmeerfieber (FMF) ist eine chronische Erkrankung, die durch wiederkehrende Fieberschübe und Serositis gekennzeichnet ist und das Risiko schwerer Komplikationen (z.B. Amyloidose) birgt. Die Behandlung von FMF gemäß EULAR Empfehlungen zielt darauf ab, akute [zum vollständigen Text gelangen Sie über die oben angegebene URL]

Published
2022
Full Text
View/download PDF

41. Autologous hematopoietic stem cell transplantation improves long term survival – data from a national registry

Author

Blank, Norbert, primary, Schmalzing, Marc, additional, Moinzadeh, Pia, additional, Oberste, Max, additional, Siegert, Elise, additional, Müller-Ladner, Ulf, additional, Riemekasten, Gabriela, additional, Günther, Claudia, additional, Kötter, Ina, additional, Zeidler, Gabriele, additional, Pfeiffer, Christiane, additional, Juche, Aaron, additional, Jandova, Ilona, additional, Ehrchen, Jan, additional, Susok, Laura, additional, Schmeiser, Tim, additional, Sunderkoetter, Cord, additional, Distler, Jörg H. W., additional, Worm, Margitta, additional, Kreuter, Alexander, additional, Keyzer, Gernot, additional, Lorenz, Hanns-Martin, additional, Krieg, Thomas, additional, Hunzelmann, Nicolas, additional, and Henes, Joerg, additional

Published
2022
Full Text
View/download PDF

43. Untersuchungen zur Versorgungsstruktur von Patienten mit familiärem Mittelmeerfieber in Deutschland

Author

Blank, Norbert, Kvacskay, Peter, Kaudewitz, Dorothee, and Lorenz, Hanns-Martin

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Das familiäre Mittelmeerfieber (FMF) ist die häufigste autoinflammatorische Erkrankung in Deutschland. Im langjährigen Verlauf kann eine AA-Amyloidose entstehen. Eine Prophylaxe mit Colchicin kann FMF Attacken und eine AA-Amyloidose reduzieren. Darüber hinaus sind Interkeukin-1-blockierende[zum vollständigen Text gelangen Sie über die oben angegebene URL], Deutscher Rheumatologiekongress 2021, 49. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 35. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), Wissenschaftliche Herbsttagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

Published
2021
Full Text
View/download PDF

48. Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis

Author

Moinzadeh, Pia, Aberer, Elisabeth, Ahmadi-Simab, Keihan, Blank, Norbert, Distler, Joerg H W, Fierlbeck, Gerhard, Genth, Ekkehard, Guenther, Claudia, Hein, Ruediger, Henes, Joerg, Herich, Lena, Herrgott, Ilka, Koetter, Ina, Kreuter, Alexander, Krieg, Thomas, Kuhr, Kathrin, Lorenz, Hanns-Martin, Meier, Florian, Melchers, Inga, Mensing, Hartwig, Mueller-Ladner, Ulf, Pfeiffer, Christiane, Riemekasten, Gabriela, Sárdy, Miklós, Schmalzing, Marc, Sunderkoetter, Cord, Susok, Laura, Tarner, Ingo H, Vaith, Peter, Worm, Margitta, Wozel, Gottfried, Zeidler, Gabriele, Hunzelmann, Nicolas, Ahrazoglu, Nil Mona, Becker, Mike Oliver, Mierau, Rudolf, Neeck, Gunther, Fiehn, Christoph, Juche, Aaron, Rubbert, Andrea, Weber, Manfred, Fischer-Betz, Rebecca, Sticherling, Michael, Burkhardt, Harald, Koehm, Michaela, Seitz, Cornelia S, Herink, Claudia, Foeldvári, Ivan, Norgauer, Johannes, Schoeffel, Dieter, Renner, Regina, Ziemer, Mirjana, Steinbrink, Kerstin, Stadler, Rudolf, Müller, Verena, Ziai, Mahzad, Karrer, Sigrid, Landthaler, Michael, Meyringer, Rotraud, Buslau, Michael, Tomsitz, Dirk, Lee, Hae- Hyuk, Lehmann, Percy, Gaebelein-Wissing, Noemi, Wagner, Marieke, Ebel, Joachim, Beyer, Christian, Varga, Rita, Bretterklieber, Agnes, Reichenberger, Frank, and Himsel, Andrea

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results